May 2022: Immunitrack presents at conferences in US, Europe and Japan

Immunitrack will be presenting its platform and latest updates in the development of novel cancer therapeutics at 3 conferences in US, Europe and Japan in May

PEGS Boston May 2-6 2022: Immunitrack is proud to co-sponsor the PEGS BOSTON Summit 2022 in Boston, that brings together scientists and researchers who are at the leading edge of biotherapeutic drug development from academia, biotech, and pharma. Immunitrack will be represented by CSO Sune Justesen, who will present a talk on Wednesday May 4th at 10 AM with the title: From T cell epitope discovery to MHC/epitope targeted therapeutics.

Nordic Health Summit Japan May 12- 13, 2022: CEO Stephan Thorgrimsen will be available for virtual partnering discussion giving you an opportunity to get an unique insight in our capabilities.

CIMT Annual Meeting May 10 -12, 2022 in Mainz: Immunitrack will be represented by CEO Stephan Thorgrimsen, COO Marie Skovgaard, and Head of Immunology Telma Lança at the meeting to network, present capabilities, and get a deeper understanding of the latest trends in the in preclinical and clinical research within cellular therapy, tumor microenvironment, therapeutic vaccination, combination therapies, and MHC/epitope targeted therapeutics.

About Immunitrack

The Major Histocompatibility Complex (MHC) is critical to the immune response. Immunitrack has world-leading expertise in manufacturing and studying MHC I and II molecules and their interactions with peptide epitopes. Using our deep knowledge in this area, we have developed the proprietary epitope screening platform technology, NeoScreen. NeoScreen accurately assays the affinity and stability of MHC/epitope interactions, and the technology has the capacity to rapidly screen libraries with thousands of (neo-)epitopes for applications within immune-oncology, vaccine production, T cell therapies and immune monitoring.

Immunitrack’s mission is to provide the pharmaceutical industry and research community with tailor made technology and reagents to select or redesign drug candidates during early R&D and to monitor the effects of lead drug candidates on patient immune responses.

Immunitrack actively collaborates with some of the leading research groups within immuno-oncology at the Johns Hopkins University Hospital, University of Columbia, Dana Farber Cancer Institute, and the National Center for Cancer Immune Therapy as well as leading pharmaceutical and biotech companies.

Find out more about our latest publications▸

Find out more about applications of our platform in: